ELF enters its August 20 earnings print carrying one of the more charged setups in the consumer space right now — short interest has jumped 20% in a single week while the stock itself has rallied 25% over the past month, creating a live tension between rebuilding bears and a market that has already repriced the name sharply higher.
The short side tells the more urgent story this week. Short interest climbed from roughly 6.7 million shares to 8.0 million between August 10 and August 18 — a 20.5% rise in seven sessions — pushing the SI level to 13.5% of the free float, one of the higher readings in the personal care space. What makes the rebuild notable is the context: in mid-July, shorts were running closer to 12 million shares, near 20% of the float, before covering aggressively through late July and early August as the stock rallied. That covering drove the stock higher; now, with ELF back above $92, fresh short positions are being put on ahead of results. Despite the rebuilt short base, the borrow market is not stressed. Availability is running at roughly 394% — meaning there are nearly four shares available to lend for every one currently borrowed — far above the tightest levels seen over the past year near 100% in mid-July. Cost to borrow is just 0.53%, barely changed on the week and near its lowest point in months. The shorts have room to add further if the earnings disappoint.
Options are nudging more cautious. The put/call ratio moved up to 0.55, above its 20-day average of 0.47 by roughly 1.4 standard deviations — not extreme by any measure, and well below the 52-week peak of 1.31, but a gentle tilt toward protection ahead of the print. The direction of the move in recent days is more telling than the level: the PCR spent most of late July near 0.41, its 52-week low, as the stock rallied. It has drifted higher in each of the past two weeks as the rally has stalled. Options traders are hedging into the event rather than pressing the bullish case.
The Street's read is constructive, but fractured on valuation. The two freshest analyst moves — both filed this morning ahead of the earnings — illustrate the divide cleanly. JP Morgan's Andrea Teixeira lowered her price target to $106 from $111 while staying Overweight, a subtle backing off from prior enthusiasm. Canaccord's Susan Anderson moved the other way, lifting her target to $110 from $97 and maintaining Buy. Earlier this month, following what appears to have been a strong quarterly update, TD Cowen raised to $110 and Bernstein — which upgraded from Market Perform to Outperform on August 5 — lifted its target to $121. UBS and Piper Sandler both raised targets after August 5 as well but stayed on the sidelines at Neutral and Neutral respectively, with UBS targeting $89 and Piper Sandler $65. The consensus mean sits at $97.75, just above the current price of $92.51 — leaving modest implied upside if the Street's mid-point is roughly right. The bull case centres on door additions internationally and continued share gains in eye and foundation products. The bear case leans on Cheek category share erosion, tough comparisons ahead, and a fiscal-year 2027 growth estimate that has already been trimmed from 16.8% to 16.6%.
Earnings history adds some texture. The two most recent prints both produced positive day-one moves: the August 2026 release recorded a 14% gain on the day, and the August 2025 result added just over 5%. The five-day moves were both positive too, at 6.6% and 5.4% respectively. That said, those were prints into a rising-short-interest environment at much higher SI levels — the setup this week, with a freshly rebuilt short base and a stock that has already run 25% in a month, is different. Worth watching is whether tomorrow's print is large enough to force another round of short covering, or whether the rebuilt bear camp holds and presses the trade.
See the live data behind this article on ORTEX.
Open ELF on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
